Valuation dashboard for ImmunityBio, Inc. (IBRX) with P/E N/A, P/B -8.32, EV/EBITDA -10.67 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms.
Analysis Summary
ImmunityBio, Inc. reported revenue of $113.3M in the most recent fiscal year, growing at a 5-year CAGR of 184.8%.
Trailing-twelve-month margins: gross margin 94.6%, operating margin -151.9%, net margin -6.0%.
At $8.29 (closing price, October 30, 2026), IBRX has negative trailing earnings (P/E not meaningful) and an ROE of 134.99%. Market capitalisation stands at $8.8B.
Balance sheet quality for IBRX: current ratio of 5.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -8.32 |
| EV / EBITDA | -10.67 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-20.45 |
| vs Current Price | -346.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | $8.8B | 135.0% | ||
| BNTX | BioNTech SE | $22.1B | 1.11 | -9.2% | |
| MRNA | Moderna, Inc. | $88.5B | 12.99 | -39.2% | |
| LEGN | Legend Biotech Corporation | $4.0B | 3.29 | -8.7% | |
| IOVA | Iovance Biotherapeutics, Inc. | $3.8B | 5.19 | -40.5% |
Price
| Price | $8.29 (closing price, October 30, 2026) |
| Market Cap | $8.8B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 134.99% |
| Return on Invested Capital | -45.01% |
| Return on Assets | -157.89% |
| Gross Margin | 94.63% |
| Operating Margin | -151.88% |
| Net Margin | -598.56% |
Related companies: BNTX · MRNA · LEGN · IOVA
Explore sector: Healthcare · Biotechnology
More sections of IBRX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks